Story Highlights
- White House economists project $529 billion in total domestic savings over 10 years from Trump’s Most Favored Nation drug-pricing framework covering 17 pharmaceutical companies
- Federal and state governments are projected to save a combined $64.3 billion on Medicaid over the same period
- Democratic senators, led by Finance Committee Ranking Member Ron Wyden, have demanded the administration publicly disclose the full terms of the pharmaceutical deals
What Happened
White House economists estimate that President Donald Trump’s deals with pharmaceutical companies to drop some of their U.S. prescription drug prices to what they charge in other countries could save $529 billion over the next 10 years. The analysis obtained by the Associated Press includes the first economy-wide projections behind a policy at the core of Trump’s pitch to voters going into November’s midterm elections.
To date, the administration has reached voluntary Most Favored Nation pricing agreements with 17 of the largest pharmaceutical manufacturers in the world. Moving forward, the administration expects to reach similar agreements with most manufacturers of sole-source brand name drugs and biologics in the nation. The 17 companies represent 86 percent of the branded drug market.
The most recent deal was announced with Regeneron, which agreed to reduce the price of its powerful cholesterol medicine, Praluent, from $537 to $225 for patients purchasing directly through TrumpRx. All new Regeneron medicines moving forward will receive MFN prices for U.S. patients. Regeneron also announced it will invest $27 billion in U.S. research, development, and manufacturing by 2029.
The voluntary MFN framework requires manufacturers to make existing drugs available to state Medicaid programs at MFN prices, which would generate $64.3 billion in federal and state savings over the next 10 years. GLP-1 users without insurance coverage are expected to save $3,000 per year, and couples undergoing in-vitro fertilization are anticipated to realize savings exceeding $6,000.
Democratic lawmakers challenged the administration’s claims. Senate Finance Committee Ranking Member Ron Wyden of Oregon and 17 Senate Democrats in April proposed a measure requiring the administration to disclose the terms of the agreements signed by pharmaceutical companies. “If these deals are so great, why is the Trump administration afraid of showing them to the public?” Wyden said. Health Secretary Robert F. Kennedy Jr. said his team would share details that did not include proprietary information or trade secrets.
Why It Matters
Drug pricing is one of the few domestic policy areas where Trump retains credible cross-partisan appeal. Roughly 60 percent of American adults report worry about affording prescription drugs, and more than 80 percent consider U.S. drug prices unreasonable. Americans pay approximately three times as much as people in other developed countries for the same prescription medications — a disparity that has persisted for decades regardless of which party controlled Washington.
The MFN framework, if it delivers on its projections, would represent the most significant reduction in American drug costs since the Medicare Part D prescription drug benefit was created in 2003. For low-income Americans on Medicaid, the elderly, and patients managing chronic conditions, the potential savings on specific drugs are substantial and real. The Praluent price cut alone — from $537 to $225 — illustrates the gap that has existed between U.S. prices and global norms.
However, significant skepticism surrounds the White House’s headline figures. Few of the details of the deals struck by the Trump administration and the 17 leading pharmaceutical companies have been made public, making it hard to independently verify the projected savings. The administration’s refusal to publish the full terms of the agreements means Congress, independent economists, and the public cannot assess whether the commitments are durable, enforceable, or sufficient.
Independent data firm 46brooklyn, which tracks brand-name drug prices, found that close to 1,000 brand drugs went up in price in January 2026. What’s more, 2025 had the highest number of list price increases ever. That trend exists simultaneously alongside the MFN deals, raising serious questions about whether overall drug cost burdens are actually declining for the average American consumer.
Economic and Global Context
The potential savings estimated by the Trump administration would be substantial given that Americans spent $467 billion on prescription drugs in 2024, according to the most recent government data available. A $529 billion savings over a decade, if real, would represent a significant restructuring of how Americans pay for innovative medicines. The analysis is premised on the idea that foreign countries would also pay more for their prescription drugs, diversifying drugmakers’ revenue sources.
Senate staff working for Sen. Bernie Sanders of Vermont released a competing analysis finding that the combined profits of 15 companies that have agreed to the drug-pricing plan jumped 66 percent over the past year, to $177 billion. The report noted that the tax cuts Trump signed into law last year exempted or delayed many of the most expensive drugs from price negotiations with Medicare. The administration countered that Sanders’ analysis was based on list prices rather than actual patient-paid prices.
The pharmaceutical tariff order signed in April — imposing 100 percent duties on patented drug imports from companies that have not struck MFN deals — provides a powerful coercive mechanism supporting the voluntary framework. Companies that participate escape the tariffs for three years, making the MFN deals commercially attractive regardless of a company’s ideological or political orientation. Since November, more than a dozen major drugmakers, including Eli Lilly, Pfizer, and Novo Nordisk, have inked deals with Trump to lower the prices of new and existing medicines.
The global pharmaceutical industry is watching the U.S. experiment carefully. If the MFN model successfully reduces American drug prices while maintaining drug company profitability through increased foreign revenues, it could reshape how wealthy nations approach pharmaceutical negotiations — a structural shift that would benefit patients worldwide.
Implications
The drug-pricing initiative represents one of the Trump administration’s clearest attempts to address a cost-of-living issue that voters rank among their top concerns. Coming amid rising gas prices and economic anxiety tied to the Iran conflict, the White House needs a politically potent domestic win, and the MFN projections are designed to provide one. The $529 billion figure will feature prominently in Republican midterm messaging.
Congress will be the next battleground. The administration is working with Congress to codify those voluntary agreements into law to ensure that patients continue to benefit from price discounts. Codification would transform a voluntary, administratively reversible arrangement into permanent statutory policy — but it would also subject the terms to public legislative scrutiny that has so far been avoided.
For patients, the most immediate implication is the expansion of TrumpRx.gov, the administration’s direct-to-consumer drug purchasing portal. While the platform currently covers a limited number of drugs — many of which have cheaper generic alternatives — its expansion could meaningfully reduce out-of-pocket costs for patients managing conditions like high cholesterol, obesity, and diabetes if the pipeline of MFN-priced drugs grows as promised.
The broader constitutional and market question is whether voluntary deals enforced by tariff threats constitute sound long-term drug policy. If a future administration abandons the tariff pressure, the incentive structure collapses. Critics on both the left and right have noted that durable drug pricing reform requires statutory authority, transparent pricing benchmarks, and independent enforcement — none of which the current framework provides.
Sources
“Trump’s drugmaker deals may save economy $529B over 10 years, White House says”
